<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2000
--------------
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
-------------- --------------
Commission File Number 0-28674
-------
CADUS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified on its Charter)
Delaware 13-3660391
- ------------------------------- -------------------
(State of Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
767 Fifth Avenue, New York, New York 10153
- ------------------------------------------ ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code (212) 702-4315
-------------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
----- -----
The number of shares of registrant's common stock, $0.01 par value, outstanding
as of April 30, 2000 was 13,144,040.
<PAGE>
CADUS PHARMACEUTICAL CORPORATION
INDEX
<TABLE>
<CAPTION>
Page No.
<S> <C>
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS 3
PART I - CONDENSED FINANCIAL INFORMATION
Item 1. Condensed Financial Statements
Condensed Balance Sheets - March 31, 2000 (unaudited)
and December 31, 1999 (audited) 4
Condensed Statements of Operations - Three Months ended
March 31, 2000 and 1999 (unaudited) 5
Condensed Statements of Cash Flows - Three Months Ended
March 31, 2000 and 1999 (unaudited) 6
Notes to Condensed Financial Statements (unaudited) 7-9
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 9-11
Item 3. Quantitative and Qualitive Disclosures About Market Risk 11
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 11
Item 2. Changes in Securities and Use of Proceeds 12
Item 3. Defaults Upon Senior Securities 12
Item 4. Submission of Matters to a Vote of Security Holders 12
Item 5. Other Information 12
Item 6. Exhibits and Reports on Form 8K 13
SIGNATURES 14
EXHIBIT INDEX 15
</TABLE>
2
<PAGE>
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS
Certain statements in this Quarterly Report on Form 10-Q constitute
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements involve known
and unknown risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to, technological uncertainties
regarding the Company's technologies, uncertainties regarding the Company's
ability to license its technologies to third parties, uncertainties regarding
the Company's future acquisition and in-licensing of technologies, the Company's
capital needs and uncertainty of future funding, risks and uncertainties
relating to the Company's ongoing litigation with SIBIA Neurosciences, Inc.
("SIBIA")*, including uncertainties relating to the outcome of appeals and the
re-examination of SIBIA's patent at issue in the litigation, the Company's
history of operating losses, the Company's dependence on proprietary technology
and the unpredictability of patent protection, intense competition in the
pharmaceutical and biotechnology industries, rapid technological development
that may result in the Company's technologies becoming obsolete, uncertainties
regarding the Company's ability to attract and retain key officers, employees
and consultants, as well as other risks and uncertainties discussed in the
Company's prospectus dated July 17, 1996.
- --------------
*SIBIA was acquired by Merck & Co. in the fourth quarter of 1999 and,
accordingly, references to SIBIA herein are references to Merck & Co. after such
date.
3
<PAGE>
CADUS PHARMACEUTICAL CORPORATION
Condensed Balance Sheets
<TABLE>
<CAPTION>
March 31, December 31,
2000 1999
--------- ------------
(Unaudited)
ASSETS
<S> <C> <C>
Current assets
Cash and cash equivalents $ 5,885,655 $ 5,082,212
Restricted cash - 13,566
Due from officer and director 10,140 294,636
Due from sale of equipment 100,000 -
Prepaid and other current assets 106,960 69,783
----------- ----------
Total current assets 6,102,755 5,460,197
Restricted cash-noncurrent 19,310,220 19,065,431
Investments in other ventures 639,236 999,590
Other assets, net 1,153,332 1,173,558
----------- -----------
Total assets $27,205,543 $26,698,776
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable $ - $ 17,644
Accrued expenses and other current liabilities 586,924 121,843
Deferred revenue 28,500 28,500
----------- -----------
Total current liabilities 615,424 167,987
Reserve for litigation damages 19,310,220 19,065,431
----------- -----------
Total liabilities 19,925,644 19,233,418
Stockholders' equity
Common stock 132,857 132,106
Additional paid-in capital 59,844,355 59,689,446
Accumulated deficit ( 52,397,238) ( 52,056,119)
Treasury stock ( 300,075) ( 300,075)
----------- -----------
Total stockholders' equity 7,279,899 7,465,358
----------- -----------
Total liabilities and stockholders' equity $27,205,543 $26,698,776
=========== ===========
</TABLE>
See accompanying notes to condensed financial statements
4
<PAGE>
CADUS PHARMACEUTICAL CORPORATION
Condensed Statements of Operations
Three Months Ended
March 31,
2000 1999
----------- -----------
(Unaudited) (Unaudited)
Revenues, principally from related $ - $ 3,038,776
parties
License fee 700,000 -
----------- -----------
Total revenues 700,000 3,038,776
----------- -----------
Costs and expenses
Research and development costs - 3,912,482
General and administrative expenses 852,462 1,315,216
----------- -----------
Total costs and expenses 852,462 5,227,698
----------- -----------
Operating loss ( 152,462) ( 2,188,922)
----------- -----------
Other (expense) income
Net interest income 71,697 337,175
Loss of equity in other ventures, net ( 360,354) ( 321,788)
Gain on sale of equipment 100,000 16,203
----------- -----------
Total (expense) income ( 188,657) 31,590
----------- -----------
Loss before income taxes ( 341,119) ( 2,157,332)
State and local taxes - 5,772
----------- -----------
Net loss ($ 341,119) ($ 2,163,104)
=========== ===========
Basic and diluted loss per share ($ 0.03) ($ 0.17)
=========== ===========
Weighted average shares of common
stock outstanding 13,102,340 13,068,940
=========== ===========
See accompanying notes to condensed financial statements
-5-
<PAGE>
CADUS PHARMACEUTICAL CORPORATION
Condensed Statements of Cash Flows
<TABLE>
<CAPTION>
Three Months Ended
March 31,
2000 1999
------------ ------------
(Unaudited) (Unaudited)
<S> <C> <C>
Cash flows from operating activities
Net loss ($ 341,119) ($ 2,163,104)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Depreciation and amortization 20,226 274,404
Loss of equity in other ventures 360,354 321,788
Gain on sale of equipment ( 100,000) -
Other non-cash gain - ( 16,203)
Reserve for litigation damages 244,789 -
Changes in assets and liabilities
Decrease in due from officer and director 284,496 -
Increase in prepaid and other current assets ( 37,177) ( 257,043)
Decrease in other assets - 81,740
Increase in deferred revenue - 579,691
Decrease in accounts payable ( 17,644) ( 163,217)
Increase (decrease) in accrued expenses
and other current liabilities 465,081 ( 1,129,593)
----------- -----------
Net cash provided by (used in) operating activities 879,006 ( 2,471,537)
----------- -----------
Cash flows from investing activities
Increase in restricted cash ( 231,223) -
Acquisition of fixed assets - ( 141,822)
Sales of fixed assets - 10,850
Patent costs - ( 167,500)
----------- -----------
Net cash used in investing activities ( 231,223) ( 298,472)
----------- -----------
Cash flows from financing activities
Proceeds from issuance of common stock
upon exercise of stock options 155,660 -
----------- -----------
Net cash provided by financing activities 155,660 -
----------- -----------
Net increase (decrease) in cash and cash equivalents 803,443 ( 2,770,009)
Cash and cash equivalents - beginning of period 5,082,212 10,975,528
----------- -----------
Cash and cash equivalents - end of period $ 5,885,655 $ 8,205,519
=========== ===========
</TABLE>
-6-
<PAGE>
See accompanying notes to condensed financial statements
CADUS PHARMACEUTICAL CORPORATION
Notes to Condensed Financial Statements
Note - 1 Organization and Basis of Preparation
The information presented as of March 31, 2000 and for the three month
period then ended, is unaudited, but includes all adjustments (consisting
only of normal recurring accruals) that the Company's management believes
to be necessary for the fair presentation of results for the periods
presented. Certain information and footnote disclosures normally included
in financial statements prepared in accordance with generally accepted
accounting principles have been omitted pursuant to the requirements of
the Securities and Exchange Commission, although the Company believes
that the disclosures included in these financial statements are adequate
to make the information not misleading. The December 31, 1999 balance
sheet was derived from audited financial statements. These financial
statements should be read in conjunction with the Company's annual report
on Form 10-K for the year ended December 31, 1999.
The results of operations for the three month period ended March 31, 2000
are not necessarily indicative of the results to be expected for the year
ending December 31, 2000.
Note - 2 Net Loss Per Share
For the three month periods ended March 31, 2000 and 1999 basic net loss
per share is computed by dividing the net loss by the weighted average
number of common shares outstanding. Diluted net loss per share is the
same as basic net loss per share since the inclusion of potential common
stock equivalents (stock options and warrants) in the computation would
be anti-dilutive.
Note - 3 Patent Litigation
In July 1996, SIBIA commenced a patent infringement action against the
Company alleging infringement by the Company of a patent concerning the
use of cells, engineered to express any type of cell surface receptor and
a reporter gene, used to report results in the screening of compounds
against target assays and seeking injunctive relief and monetary damages.
After trial, on December 18, 1998, the jury issued a verdict in favor of
SIBIA and awarded SIBIA $18.0 million in damages. On January 29, 1999 the
United States District Court granted SIBIA's request for injunctive
relief that precludes the Company from using the method claimed in
SIBIA's patent. On February 26, 1999, the United States District Court
denied the Company's motions to set aside the jury verdict, to grant a
new trial and to reduce or set aside the $18.0 million judgment awarded
by the jury. The Company has appealed the judgment. The appeal will be
heard by the Court of Appeals for the Federal Circuit in Washington, D.C.
All briefs have been filed and the Court of Appeals heard oral argument
on March 9, 2000. In order to stay execution pending appeal of the $18.0
million judgment obtained by SIBIA, in March 1999, the Company deposited
$18.5 million in escrow to secure payment of the judgment in the event
the Company were to lose the appeal. Such $18.5 million was classified
as "restricted cash-noncurrent" and the Company's "cash and cash
equivalents" was reduced by $18.5 million. The Company recorded a reserve
for litigation damages of $18.5 million in the
-7-
<PAGE>
statement of operations for the year ended December 31, 1998. Interest
earned on the restricted cash has been added to the reserve for
litigation damages, which was $19.3 million at March 31, 2000.
In January 1999, the U.S. Patent and Trademark Office granted the
Company's request to re-examine the patent issued to SIBIA that was the
subject of the litigation. In March 2000, the Patent Office issued an
office action rejecting all claims of SIBIA's patent. This office action
is an initial determination only to which SIBIA will have an opportunity
to respond. The Patent Office is not expected to issue a final decision
for several months. A final decision by the Patent Office that SIBIA's
patent is invalid would take precedence over the outstanding jury verdict
and judgment. There can be no assurance, however, that the Patent and
Trademark Office will issue a final decision finding SIBIA's patent to be
invalid.
Note - 4 Asset Sale
On July 30, 1999 the Company sold to OSI Pharmaceuticals, Inc. ("OSI"),
pursuant to an asset purchase agreement, various drug discovery assets
and ceased its drug discovery operations and research efforts for
collaborators as a result of this transaction. The Company terminated all
employees that were not hired by OSI or who did not voluntarily resign,
except for the Chief Executive Officer. The Company retained ownership of
all its other assets including its core yeast technology for developing
drug discovery assays, its collection of over 25,000 proprietary yeast
strains, human and mammalian cell lines, and genetic engineering tools,
its joint ownership of the human orphan G protein-coupled receptors
identified pursuant to its collaboration with Genome Therapeutics
Corporation, its proprietary software, its genomics databases related to
G protein-coupled receptors, all assays and technologies reverting to it
from its collaboration with Bristol -Myers Squibb Company, a 30% equity
position in Axiom Biotechnologies, Inc., the Company's cash and cash
equivalents, and the funds that were being held in escrow pending appeal
of the verdict in favor of SIBIA.
Note - 5 Related Party Transaction
In August 1998, the Company guaranteed the payment of a $286,000 loan
made to a Board member and secured its guarantee obligation with cash
collateral of $286,000. In August 1999, the lender called on the
guarantee and foreclosed on the cash collateral. The director executed an
interest bearing promissory note in the amount of $286,000 in favor of
the Company, which was payable, together with accrued interest, on August
31, 2000. The amount owed as of December 31, 1999 is included in due from
officer and director. This note was repaid in its entirety in March 2000.
Note - 6 Non-Exclusive License of Yeast Technology
In February 2000, the Company licensed to OSI, on a non-exclusive basis,
its yeast technologies, including various reagents and its library of
over 30,000 yeast strains, and its bioinformatics software. OSI paid to
the Company a license fee of $100,000 and an access fee of $600,000,
which has been recorded as license fee revenue in the quarter ended
March 31, 2000. OSI is also obligated to pay an annual maintenance fee of
$100,000 until 2010 and a supplemental license fee of $250,000 if the
injunction obtained by SIBIA is lifted or dissolved.
Note - 7 New Accounting Pronouncements
On December 3, 1999, the Securities and Exchange Commission ("SEC")
issued Staff Accounting Bulletin No. 101 - "Revenue Recognition in
Financial Statements" ("SAB No. 101"). SAB No. 101 provides the SEC
staff's views on the recognition of revenue including nonrefundable
technology access fees received by biotechnology companies in connection
with research collaborations with third parties. SAB No. 101 states that
in certain circumstances the SEC staff believes that up-front fees, even
if nonrefundable, should be deferred and recognized systematically over
the term of the research arrangement. SAB No. 101A, which amends the
implementation date for SAB No. 101, requires registrants with a fiscal
year that begins between December 16, 1999 and March 15, 2000 to adopt
the accounting guidance contained therein by no later than the second
fiscal quarter of the fiscal year beginning after December 15, 1999. The
Company is currently assessing the financial impact of complying with SAB
No. 101 and has not yet determined whether applying the accounting
guidance of SAB No. 101 will have a material effect on its financial
position or results of operations.
-8-
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Overview
The Company was incorporated in 1992 and until July 30, 1999, devoted
substantially all of its resources to the development and application of novel
yeast-based and other drug discovery technologies. On July 30, 1999, the Company
sold its drug discovery assets to OSI Pharmaceuticals, Inc. ("OSI") and ceased
its internal drug discovery operations and research efforts for collaborative
partners. The Company terminated all employees who were not hired by OSI or who
did not voluntarily resign, except for the Chief Executive Officer who resigned
in April 2000.
The Company has incurred operating losses in each year since its inception,
including net losses of approximately $341,000 during the three-month period
ended March 31, 2000. At March 31, 2000, the Company had an accumulated deficit
of approximately $52.4 million, which reflects an $18.5 million charge for
litigation damages with respect to the patent infringement litigation with
SIBIA. The Company's losses have resulted principally from costs incurred in
connection with its research and development activities and from general and
administrative costs associated with the Company's operations. These costs have
exceeded the Company's revenues and interest income. As a result of the sale of
its drug discovery assets to OSI and the cessation of its internal drug
discovery operations and research efforts for collaborative partners, the
Company ceased to have research funding revenues and substantially reduced its
operating expenses. The Company expects to generate revenues in the future only
if it is able to license its technologies.
Results of Operations
Three Months Ended March 31, 2000 and March 31, 1999
Revenues
Revenues for the three months ended March 31, 2000 decreased to $700,000 from
$3.0 million for the same period in 1999. This decrease was attributable
primarily to the Company having ceased research efforts for collaborators and,
therefore, not receiving any research funding for the first quarter of 2000. The
Company's revenues for the first quarter of 2000 were derived solely from its
licensing of its yeast technology to OSI.
Operating Expenses
The Company's research and development expenses for the three months ended March
31, 2000 decreased to $0 from $3.9 million for the same period in 1999. This
decrease was attributable to the Company having ceased its drug discovery
operations and research efforts for collaborators and having no research
personnel after its asset sale in July 1999.
General and administrative expense decreased to $852,462 for the three months
ended March 31, 2000 from $1.3 million for the same period in 1999. This
decrease was attributable primarily to the elimination of facility related
expenses and the reduction in administrative personnel. For the three months
ended March 31, 2000, the Chief Executive Officer's compensation was $580,000,
which includes $497,500 in severance pay.
-9-
<PAGE>
Net Interest Income
Interest income for the three months ended March 31, 2000 decreased to
$71,697 from $337,175 for the same period in 1999. The decrease is attributable
primarily to the decrease in the Company's unrestricted cash equivalent balances
as compared to the prior year's three-month period.
Equity In Other Ventures
For the three months ended March 31, 2000 the Company recognized a net loss of
$360,354 in its investment in Axiom Biotechnologies, Inc. and Laurel Partners
Limited Partnership. The loss for the same period in 1999 was $321,788.
Net Loss
The net loss for the three months ended March 31, 2000 decreased to $341,119
from $2.2 million for the same period in 1999. This decrease can be attributed
to a decrease in the Company's operating expenses which was partially offset by
a decrease in revenues.
Liquidity and Capital Resources
At March 31, 2000 the Company held cash and cash equivalents exclusive of
restricted cash of $5,885,655. The Company's working capital at March 31, 2000
was $5,487,331.
On July 30, 1999, the Company sold its drug discovery assets to OSI and ceased
its internal drug discovery operations and research efforts for collaborative
partners. Pursuant to such sale transaction, OSI assumed, among other things,
the Company's lease to the Company's research facility in Tarrytown, New York
and the Company's equipment lease with GECC. The Company terminated all
employees who were not hired by OSI or who did not voluntarily resign, except
for its Chief Executive Officer. As a result of the foregoing, the Company
ceased to have revenues and substantially reduced its operating expenses. The
Company expects to generate revenues in the future only if it is able to license
its technologies.
In February 2000, the Company licensed to OSI, on a non-exclusive basis, its
yeast technologies. OSI paid to the Company a license fee of $100,000 and an
access fee of $600,000. OSI is also obligated to pay an annual maintenance fee
of $100,000 until 2010 and a supplemental license fee of $250,000 if the
injunction obtained by SIBIA is lifted or dissolved.
The Company believes that its existing capital resources, together with interest
income, will be sufficient to support its current and projected funding
requirements through the end of 2001. This forecast of the period of time
through which the Company's financial resources will be adequate to support its
operations is a forward-looking statement that may not prove accurate and, as
such, actual results may vary. The Company's capital requirements may vary as a
result of a number of factors, including the transactions, if any, arising from
the Company's efforts to license its technologies and otherwise realize value
from its assets, the transactions, if any, arising from the Company's efforts to
acquire technologies or products or to acquire or invest in companies, expenses
of pursuing such transactions and the outcome of its appeal of the judgment in
the SIBIA patent litigation.
-10-
<PAGE>
New Accounting Pronouncements
On December 3, 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin No. 101 - "Revenue Recognition in Financial
Statements" ("SAB No. 101"). SAB No. 101 provides the SEC staff's views on the
recognition of revenue including nonrefundable technology access fees received
by biotechnology companies in connection with research collaborations with third
parties. SAB No. 101 states that in certain circumstances the SEC staff believes
that up-front fees, even if nonrefundable, should be deferred and recognized
systematically over the term of the research arrangement. SAB No. 101A, which
amends the implementation date for SAB No. 101, requires registrants with a
fiscal year that begins between December 16, 1999 and March 15, 2000 to adopt
the accounting guidance contained therein by no later than the second fiscal
quarter of the fiscal year beginning after December 15, 1999. The Company is
currently assessing the financial impact of complying with SAB No. 101 and has
not yet determined whether applying the accounting guidance of SAB No. 101 will
have a material effect on its financial position or results of operations.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The Company is not a party to any material legal proceedings other than
SIBIA Neurosciences, Inc. v. Cadus Pharmaceutical Corporation and an
arbitration proceeding commenced by Philip N. Sussman, the former
Senior Vice President, Finance and Corporate Development, and Chief
Financial Officer of the Company.
(a) SIBIA commenced an action on July 9, 1996 in the United States
District Court for the Southern District of California alleging
infringement by the Company of a patent covering the use of cells,
engineered to express any type of cell surface receptor and a reporter
gene, used to report results in the screening of compounds against
target assays, and seeking injunctive relief and monetary damages.
After trial, on December 18, 1998, the jury issued a verdict in favor
of SIBIA and awarded SIBIA $18.0 million in damages. On January 29,
1999, the United States District Court granted SIBIA's request for
injunctive relief that precludes the Company from using the method
claimed in SIBIA's patent. On February 26, 1999, the United States
District Court denied the Company's motions to set aside the jury
verdict, to grant a new trial and to reduce or set aside the $18.0
million damage award by the jury. The Company has appealed the
judgment. The appeal will be heard by the Court of Appeals for the
Federal Circuit in Washington, D.C. All briefs have been filed and the
Court of Appeals heard oral argument on March 9, 2000. In order to stay
execution pending appeal of the $18.0 million judgment obtained by
SIBIA, in March 1999, the Company deposited $18.5 million in escrow to
secure payment of the judgment in the event the Company were to lose
the appeal. If the Company is not successful in materially reducing or
setting aside the $18.0 million damage award on appeal, the business,
financial condition and results of operations of the Company will be
materially adversely affected. The costs of and the diversion of
Company resources associated with this litigation have had a material
adverse effect on the business, financial condition, results of
operations and liquidity of the Company.
-11-
<PAGE>
In January 1999, the U.S. Patent and Trademark Office granted the
Company's request to re-examine the patent issued to SIBIA that was the
subject of the litigation. In March 2000, the Patent Office issued an
office action rejecting all claims of SIBIA's patent. This office
action is an initial determination only to which SIBIA will have an
opportunity to respond. The Patent Office is not expected to issue a
final decision for several months. A final decision by the Patent
Office that SIBIA's patent is invalid would take precedence over the
outstanding jury verdict and judgment. There can be no assurance,
however, that the Patent Office will issue a final decision finding
SIBIA's patent to be invalid.
(b) On October 4, 1999, Philip N. Sussman, the former Senior Vice
President, Finance and Corporate Development, and Chief Financial
Officer of the Company, commenced an arbitration proceeding against the
Company seeking severance pay of approximately $525,000. The Company
believes that Mr. Sussman is not entitled to such severance pay and
intends to vigorously defend the action.
Item 2. Changes in Securities and Use of Proceeds
Nothing to Report.
Item 3. Defaults Upon Senior Securities
Nothing to Report
Item 4. Submission of Matters to a Vote of Security Holders
Nothing to Report
Item 5. Other Information
Nothing to Report
Item 6. Exhibits and Reports on Form 8-K.
(a) The exhibits listed in the Exhibit Index are included in this
report.
(b) Reports on Form 8-K.
None
-12-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CADUS PHARMACEUTICAL CORPORATION
(Registrant)
Date: May 12, 2000 By: /s/ Russell D. Glass
---------------------
Russell D. Glass
President and Chief Executive Officer
(Authorized Officer and Principal
Financial Officer)
-13-
<PAGE>
EXHIBIT INDEX
The following exhibits are filed as part of this Quarterly Report on
Form 10-Q:
Exhibit No. Description
----------- -----------
10.29 Yeast Technology License Agreement, dated
as of February 15, 2000, between the
Company and OSI Pharmaceuticals, Inc.
(Exhibits to the Yeast Technology License
Agreement have been intentionally omitted.
The Company hereby undertakes to furnish
supplementally to the Securities and
Exchange Commission upon request a copy of
the omitted exhibits).
27 Financial Data Schedule
-14-
<PAGE>
YEAST TECHNOLOGY LICENSE AGREEMENT
YEAST TECHNOLOGY LICENSE AGREEMENT (the "Agreement"), dated as of
February 15, 2000, by and between Cadus Pharmaceutical Corporation, a Delaware
corporation with offices at 767 Fifth Avenue, New York, New York 10153 ("CADUS")
and OSI Pharmaceuticals, Inc., a Delaware corporation with offices at 106
Charles Lindbergh Boulevard, Uniondale, New York 11533 ("OSI").
W I T N E S S E T H:
- - - - - - - - - -
WHEREAS, CADUS is the owner of, or has acquired the rights to, CADUS
Technology; and
WHEREAS, OSI desires to obtain a non-exclusive license for the use and
practice of CADUS Technology, and CADUS is willing to grant such non-exclusive
license, upon the terms and conditions hereinafter set forth;
NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual covenants and agreements of the Parties contained in this Agreement, the
Parties agree as follows:
1. DEFINITIONS
For the purposes of this Agreement, the following terms shall have the
meanings set forth in this Section 1:
<PAGE>
"CADUS Patents" shall mean all patents and patent applications to
the extent they claim CADUS Technology, which are or become owned by CADUS or to
which CADUS otherwise has, now or in the future, the right to grant licenses.
Included within the definition of CADUS Patents are all continuations,
continuations- in-part, divisions, patents of addition, reissues, renewals,
extensions, registrations, confirmations, re-examinations thereof and any
provisional applications.
"CADUS Technology" shall mean all proprietary inventions,
improvements, discoveries, claims, formulae, processes, trade secrets and
technologies owned by CADUS or to which CADUS has the right to grant licenses or
sublicenses as of the Effective Date, relating to technology involving the
transfection, expression and functional coupling of Targets into yeast cells and
mammalian cell lines and the development of such yeast cells and mammalian cell
lines as screening assays for the discovery of human diagnostics and
therapeutics. "CADUS Technology" shall include, without limitation, the
bioinformatics databases owned by CADUS required to fully utilize and develop
the CADUS Technology.
"Covered Material" means a Hybrid Yeast Cell, a Plasmid, a
Mammalian Cell Line or any material that is a Derivative of it. "Covered
Material" includes a Derivative of a Derivative of a Hybrid Yeast Cell, a
Plasmid or a Mammalian Cell Line.
"Derivative" shall mean any of the following: (i) any substance
derived from or expressed or modified by a Hybrid Yeast Cell, a Plasmid or a
Mammalian Cell Line; (ii) any substance that contains or incorporates a Hybrid
Yeast Cell, a Plasmid or a Mammalian Cell Line; or (iii) any fragment of any of
the foregoing.
2
<PAGE>
"Effective Date" shall mean the date of this Agreement as set
forth at the beginning of this Agreement.
"Hybrid Yeast Cells" shall mean genetically modified yeast cells,
which are owned by CADUS.
"Injunction" shall mean the injunction, dated February 23, 1999,
issued by the United States District Court for the Southern District of
California in the SIBIA Litigation.
"Mammalian Cell Lines" shall mean mammalian cell lines which are
owned by CADUS.
"Party" shall mean CADUS or OSI and, when used in the plural,
shall mean CADUS and OSI.
"Person" shall mean any natural person, corporation, firm,
business trust, joint venture, association, university, organization, company,
partnership or other business entity, or any government or any agency or
political subdivision thereof.
"Plasmid" shall mean plasmids which are owned by CADUS.
"Product" shall mean any compound, formulation or composition
whose utility is identified using CADUS Technology.
"proprietary" shall mean, with respect to intellectual property,
intellectual property that is (in whole or in part) not in the public domain at
the time of transfer to the other party.
3
<PAGE>
"SIBIA Litigation" shall mean SIBIA Neurosciences, Inc. v. Cadus
Pharmaceutical Corporation, Civil Action Number 961231 1EG POR.
"Target" shall mean any biological molecular entity that provides
a specific interaction with compounds, extracts, broths or other screening
samples.
"Third Party" shall mean any Person who or which is neither a
Party nor an affiliate of a Party.
2. REPRESENTATIONS AND WARRANTIES.
2.1 Representations and Warranties of Both Parties Each Party
represents and warrants to the other Party that: (i) it is free to enter into
this Agreement; (ii) in so doing, it will not violate any other agreement to
which it is a party; (iii) it has taken all corporate action necessary to
authorize the execution and delivery of this Agreement and the performance of
its obligations under this Agreement; and (iv) this Agreement constitutes a
valid and binding obligation of such Party and is enforceable against it in
accordance with its terms.
2.2 Representations and Warranties of CADUS. CADUS hereby represents
and warrants to OSI that:
(a) It is the owner, or a licensee, of the CADUS Technology and
CADUS Patents and has the right to grant licenses therefor; and
(b) During the term of this Agreement, it shall maintain its
licenses to Cadus Technology licensed to it.
4
<PAGE>
3. GRANT OF LICENSE
3.1 License Grant. Subject to the terms and conditions of this
Agreement, CADUS hereby grants to OSI , a non-exclusive, royalty-free, worldwide
right and license to use and practice the CADUS Technology and CADUS Patents
other than to identify and select compounds in a method that infringes any of
the claims of United States Patent No. 5,401,629 so long as any such claim
remains outstanding and in effect.
3.2 No Violation of Injunction. OSI acknowledges that it has reviewed
the Injunction and covenants that, in practicing the CADUS Technology and CADUS
Patents, OSI will not violate the terms of the Injunction or cause CADUS to be
in violation of the terms of the Injunction so long as the Injunction remains
outstanding and in effect.
3.3 No Right to Sublicense. OSI shall not have the right to sublicense
its rights hereunder. During the term of this Agreement, OSI may practice the
CADUS Technology and CADUS Patents in connection with assay development and
screening for Third Parties pursuant to collaborative research programs with
such Third Parties ("Third Party Collaborators"), provided that such assay
development and screening takes place at OSI's facilities and is conducted by
OSI personnel. In addition, a Third Party Collaborator may utilize assays
developed by OSI using CADUS Technology to test compounds solely during the term
and in furtherance of its collaboration with OSI.
3.4 Reservation of Rights. CADUS is retaining all rights to the CADUS
Technology and CADUS Patents that are not specifically being licensed to OSI
pursuant to Section 3.1 hereof.
5
<PAGE>
3.5 Ownership of CADUS Technology. The Parties acknowledge and agree
that all CADUS Technology is now and shall be solely owned or licensed by CADUS
and that OSI shall have no right, title or interest therein except as explicitly
set forth in this Agreement.
3.6 Provision of Access to CADUS Technology. Subject to the
confidentiality provisions of Section 10.1, CADUS shall provide to OSI: (i) an
electronic copy of its database of Covered Material, (ii) an electronic copy of
its database of G protein-coupled receptors that are not proprietary to any
Third Party and (iii) an electronic copy of the bioinformatics databases owned
by CADUS required to fully utilize and develop the CADUS Technology.
4. ACCESS TO COVERED MATERIAL.
4.1 Access to Covered Material. On or prior to the date hereof, CADUS
has delivered to OSI an aliquot of each Covered Material listed on Exhibit A
annexed hereto. During the term of this Agreement, CADUS shall provide to OSI an
aliquot of each Covered Material not listed on Exhibit A annexed hereto that is
requested by OSI in accordance with the procedure set forth below. OSI may
request a Covered Material by sending to Dr. James Broach at Department of
Molecular Biology, Lewis Thomas Laboratory, Princeton University, Washington
Road, Princeton, New Jersey 08544 (or to such other person at such other place
as CADUS may hereafter designate) a written request for such Covered Material.
OSI shall pay to Dr. James Broach or such other person the incremental cost of
retrieval and shipment of such Covered Material promptly after the receipt of an
invoice therefor. CADUS shall ship such Covered Material to OSI within 15 days
of its receipt of such written request. OSI shall have the right to use Covered
Material only during the term of this Agreement.
6
<PAGE>
4.2 No Transfer of Covered Material. OSI shall not provide any Covered
Material to any Third Party other than a contract research organization or Third
Party Collaborator that has executed a confidentiality agreement with respect to
the Covered Material containing provisions similar to Section 10 hereof. OSI
shall promptly destroy all Covered Material in its possession upon the
termination of this Agreement. OSI will not take or send Covered Material to any
location other than the facilities of OSI or a contract research organization or
Third Party Collaborator that has executed a confidentiality agreement with
respect to the Covered Material containing provisions similar to Section 10
hereof without CADUS's prior written consent.
4.3 No Warranties As To Covered Material. Any Covered Material
delivered pursuant to this Agreement is understood to be experimental in nature
and may have hazardous properties. It is supplied AS IS. CADUS MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE COVERED MATERIAL WILL
NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
4.4 Compliance with Laws. OSI agrees to use the Covered Material in
compliance with all applicable statutes and regulations including, for example,
those relating to research involving the use of animals or recombinant DNA.
5. LICENSE AND MAINTENANCE FEES.
5.1 License and Access Fees. In consideration of the license granted to
OSI by CADUS pursuant to Section 3.1 hereof, OSI shall pay to CADUS a license
fee of $100,000 payable on the Effective Date. In consideration of the access to
CADUS
7
<PAGE>
Technology (Section 3.6) and to Covered Material (Section 4.1), OSI shall pay to
CADUS an access fee of $600,000 payable on the Effective Date.
5.2 Maintenance Fee. OSI shall also pay to CADUS an annual maintenance
fee of $100,000 payable on each of the first ten anniversaries of the Effective
Date during the term of this Agreement.
5.3 Special Fee. If the Injunction is lifted or dissolved, OSI shall
pay to CADUS a supplemental license fee of $250,000 within ten (10) days after
the receipt of notice of the lifting or dissolution of the Injunction.
5.4 No Refunds. None of the fees paid by OSI to CADUS pursuant to
Section 5 shall be refundable for any reason whatsoever.
6. PATENTS.
6.1 No Obligation to Prosecute or Maintain Patents. CADUS shall not
have any obligation to prosecute or maintain CADUS Patents. Notwithstanding the
foregoing, CADUS shall not abandon any of the United States patent applications
constituting CADUS Patents set forth on Exhibit B until such time as (i) the
corresponding foreign patent application has been published or (ii) CADUS has
taken the appropriate steps with the United States Patent and Trademark Office
to dedicate such patent application to the public.
6.2 Infringement. OSI shall give CADUS prompt written notice of any
claim or allegation received by it that the use of CADUS Technology constitutes
an infringement of a Third Party patent or patents. OSI shall have the primary
right to control the defense of any such claim against OSI with counsel of its
own choosing.
8
<PAGE>
CADUS agrees to cooperate with OSI, at OSI's expense, in any reasonable manner
deemed by OSI to be necessary in defending such action. Notwithstanding the
foregoing, CADUS shall, in its own discretion and at its own cost, be entitled
to participate through counsel of its own choosing in any such action.
6.3 Patent Enforcement.
(a) With respect to any alleged infringement involving
a claim(s) of any patents covering CADUS Technology, CADUS shall have the first
right, but not the duty, to institute patent infringement actions against third
parties. If CADUS does not institute an infringement proceeding against an
offending third party, OSI shall have the right, but not the duty, to institute
such an action.
(b) The costs and expenses of any action instituted
pursuant to this Section 6.3 (including fees of attorneys and other
professionals) shall be borne by the Party instituting the action, or, if the
Parties elect to cooperate in instituting and maintaining such action, such
costs and expenses shall be borne by the Parties in such proportions as they may
agree in writing. Each Party shall execute all necessary and proper documents
and take such actions as shall be appropriate to allow the other Party to
institute and prosecute such infringement actions (if such other Party has the
right to institute and prosecute such infringement actions pursuant to this
Section 6.3). Any award paid by Third Parties as a result of such an
infringement action (whether by way of settlement or otherwise) shall be paid to
the Party who instituted and maintained such action, or, if both Parties
instituted and maintained such action, such award shall be allocated among the
Parties in proportion to their respective contributions to the costs and
expenses incurred in such action, or as they may have otherwise agreed.
Notwithstanding the above, CADUS shall receive 25% of any such award by way of
settlement or otherwise after deducting legal and other reasonable expenses.
9
<PAGE>
7. TERM AND TERMINATION
7.1 Term. This Agreement shall become effective as of the Effective
Date and shall remain in full force and effect until terminated as provided in
this Section 7.
7.2 Termination by OSI. OSI may terminate this Agreement at any time by
giving CADUS thirty (30) days prior written notice of termination.
7.3 Termination for Breach. Failure by either Party to comply with any
of the obligations contained in this Agreement shall entitle the other Party to
give to the defaulting Party notice specifying the nature of the default and
requiring it to cure such default. If such default is not cured within 30 days
after the receipt of such notice, the notifying Party shall be entitled, without
prejudice to any of its other rights conferred on it by this Agreement, in
addition to any other remedies available to it by law or in equity, to terminate
this Agreement by giving written notice to take effect immediately upon delivery
of such notice. The right of either Party to terminate this Agreement shall not
be affected in any way by its waiver or failure to take action with respect to
any previous default.
7.4 Termination for Bankruptcy. CADUS may terminate this Agreement if,
at any time, OSI shall file in any court or agency pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver or
trustee of OSI or of its assets, or if OSI proposes a written agreement of
composition or extension of its debts, or if OSI shall be served with an
involuntary petition against it, filed in any insolvency proceeding, and such
petition shall not be dismissed within sixty (60) days
10
<PAGE>
after the filing thereof, or if OSI shall propose or be a party to any
dissolution or liquidation, or if OSI shall make an assignment for the benefit
of creditors.
7.5 No Termination in Event of CADUS Bankruptcy. CADUS and OSI
acknowledge that this Agreement and the license granted herein comes within
Section 365(n) of Title 11, United States Code (the "Bankruptcy Code"). CADUS
acknowledges that if CADUS, as a debtor in possession, or a trustee in
bankruptcy in a case under the Bankruptcy Code, rejects the Purchase Agreement
or this Agreement, OSI may elect to retain its rights under this Agreement as
provided in Section 365(n) of the Bankruptcy Code. Upon written request of OSI
to CADUS or the bankruptcy trustee, CADUS shall not interfere with the rights of
OSI as provided in this Agreement.
7.6 Survival of Certain Provisions. The following provisions of this
Agreement will survive the termination of this Agreement: Sections 2.1, 3.5,
4.2, 4.3, 4.4, 8, 9, 10 and 11.
8. DISPUTE RESOLUTION
8.1 Dispute Resolution. If one of the Parties hereto declares that a
dispute between the Parties has arisen related to this Agreement, such dispute
shall, in the first instance, be the subject of good faith negotiations between
the Parties to resolve such dispute. Should the negotiations not lead to a
settlement of the dispute within thirty (30) days of the date of the meeting,
the Parties shall refer the dispute to a mutually acceptable mediation service
to resolve the dispute. The mediation shall be attended by individuals from
within each Party who have decision-making authority with respect to the matter
in question. If the mediation does not lead to a settlement of the dispute
within thirty (30) days of the date of the meeting, then the Parties shall
submit the issue to arbitration before a panel of arbitrators under the
commercial rules of the
11
<PAGE>
American Arbitration Association. Unless the Parties otherwise agree, the
arbitration will be held in New York, New York. The panel of arbitrators shall
consist of three parties: one selected by each Party, as well as a disinterested
third party that the two arbitrators shall name. The third arbitrator shall be a
person who has had experience in the business of biotechnology licensing. If a
qualified person in this field cannot be found and agreed upon, the two
arbitrators shall use their own discretion and select a third arbitrator with
qualifications as they deem appropriate. The three arbitrators shall be given
full power to hear and finally determine and dispose of all disputes between the
parties that may arise from or that are related to this Agreement. The
arbitrator will make their ruling in writing no later than thirty (30) days
after the hearing. The decision of two of the three arbitrators will be binding
on the Parties. No Party has a right to appeal the ruling, to any court or
otherwise. Judgment upon the decision rendered may be entered in any court
having jurisdiction or application may be made to such court of a judicial
acceptance of the award and an order of enforcement, as the case may be. Each
Party shall pay its own attorney's fees. All fees and expenses payable with
respect to the mediation and arbitration proceedings shall be shared by both
Parties during the course of the mediation and arbitration proceedings, but, in
the case of arbitration, shall be reimbursed in favor of the prevailing Party
after the arbitration ruling is rendered. Notwithstanding this Section 8.1,
CADUS shall have the right to seek injunctive relief pursuant to Section 11.12
hereof.
9. INDEMNITY, INSURANCE AND REPRESENTATIONS
9.1 Indemnity. OSI agrees to indemnify, hold harmless and defend CADUS,
its directors, officers, employees and agents against any and all claims, suits,
losses, damages, costs, fees and expenses, including attorney fees, resulting
from or arising out of the exercise of this license, including from OSI's use,
storage or disposal
12
<PAGE>
of the Covered Material or manufacture, distribution or sale or Product(s),
unless such losses, damages, costs, fees and expenses arise from the use of
CADUS Technology constituting an infringement of a Third Party patent or
patents. CADUS shall not be responsible for the negligence or intentional
wrongdoing of OSI.
9.2 Insurance. At the time of its sale of Product(s), OSI shall
maintain in force at its sole cost and expense, with reputable insurance
companies, general liability insurance and products liability insurance coverage
that names CADUS as a beneficiary and protects against liability under Section
9.1 above in such amount as is customary in the industry. CADUS shall have the
right to ascertain from time to time that such coverage exists, such right to be
exercised in a reasonable manner.
9.3 Warranties and Representations. Nothing in this Agreement shall be
deemed to be a representation or warranty by CADUS of the validity of any of the
CADUS Patents or the accuracy, safety, efficacy or usefulness for any purpose of
any technology licensed hereunder. CADUS shall have no obligation, express or
implied, to supervise, monitor, review or otherwise assume responsibility for
the production, manufacture, testing, marketing or sale of any Product(s), and
CADUS shall have no liability whatsoever to OSI or any Third Parties for or on
account of any injury, loss or damage, of any kind or nature, sustained by, or
any damage assessed or asserted against, or any other liability incurred by or
imposed upon OSI, its affiliates or sublicensees, or any other person or entity
arising out of or in connection with or resulting from: (i) the production, use
or sale of any Product(s); (ii) the use of any CADUS Technology; or (iii) any
advertising or other promotional activities with respect to any of the
foregoing.
10. CONFIDENTIALITY.
13
<PAGE>
10.1 CADUS Technology. All CADUS Technology and Covered Material that
is disclosed or provided to OSI shall be maintained by OSI in confidence and
shall not be disclosed to any other person, firm or agency, governmental or
private, or used for purposes other than those set forth in this Agreement,
without the prior written consent of CADUS, except to the extent that such
information:
(i) is known at the time of its receipt by OSI as documented
by written records dated prior to such disclosure;
(ii) is in the public domain other than through the fault of
OSI;
(iii) is subsequently disclosed to OSI by a Third Party who
may lawfully do so and who is not under an obligation of confidentiality to
CADUS; or
(iv) is required to be disclosed in a judicial or
administrative proceeding after legal remedies for maintaining the subject
matter in confidence have been exhausted.
10.2 Duration of Confidentiality Obligation. OSI's obligations of
confidentiality shall continue during the term of this Agreement and for a
period of five years thereafter.
11. MISCELLANEOUS
11.1 Relationship of Parties. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties. No Party shall incur any debts or make
any commitments for the other.
14
<PAGE>
11.2 Assignment. Neither Party shall be entitled to assign its rights
or transfer its obligations hereunder without the express written consent of the
other Party hereto, except that CADUS may assign its rights and transfer its
obligations hereunder to a purchaser of CADUS Technology and OSI may assign its
rights and transfer its obligations hereunder to any assignee of all or
substantially all of its assets. No assignment and transfer shall be valid and
effective unless and until the assignee/transferee shall agree in writing to be
bound by the provisions of this Agreement.
11.3 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.
11.4 Notice. Any notice or request required or permitted to be given
under or in connection with this Agreement (other than requests pursuant to
Section 4.1 hereof) shall be deemed to have been sufficiently given if in
writing and personally delivered or sent by registered or certified mail (return
receipt requested), facsimile transmission (receipt verified), express courier
service (signature required), or telegram, prepaid, to the Party for which such
notice is intended, at the address set forth for such Party below:
(a) In the case of OSI, to:
OSI Pharmaceuticals, Inc.
106 Charles Lindbergh Boulevard
Uniondale, New York 11533
Attention: President
Facsimile No.: (516) 745-6429
15
<PAGE>
with a copy to:
Squadron, Ellenoff, Plesent & Sheinfeld, LLP
551 Fifth Avenue
New York, New York 10176
Attention: Joel I. Papernik, Esq.
Facsimile No.: (212) 697-6686
(b) In the case of CADUS, to:
Cadus Pharmaceutical Corporation
767 Fifth Avenue
New York, New York 10153
Attention: President
Facsimile No.: (212) 750-5841
With a copy to:
Morrison Cohen Singer & Weinstein, LLP
750 Lexington Avenue
New York, New York 10022
Attention: Salomon R. Sassoon, Esq.
Facsimile No.: (212) 735-8708
or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof. If sent by mail, facsimile transmission,
express courier service, or telegram, the date of mailing or transmission shall
be deemed to be the date on which such notice or request has been given.
11.5 Use of Name. Except as otherwise provided herein, neither Party
shall have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party for any purpose in connection with the performance of this Agreement.
16
<PAGE>
11.6 Waiver. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for the future, or of any subsequent
breach hereof. All rights, remedies, undertakings, obligations and agreements
contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of
either Party.
11.7 Export Control Laws. OSI agrees to abide by all laws and
regulations of the United States controlling the export of technical data,
computer software, biological materials, laboratory prototypes and other
commodities and technology.
11.8 Severability. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement, and the Parties shall negotiate in good faith to modify this
Agreement to preserve (to the extent possible) their original intent.
11.9 Amendment. No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.
11.10 Governing Law. This Agreement shall be governed by, and construed
and enforced in accordance with, the laws of the State of New York, without
regard to its choice of law principles.
17
<PAGE>
11.11 Entire Agreement. This Agreement sets forth the entire agreement
and understanding between the Parties as to the subject matter hereof and
supercedes any previous agreements and understandings between the Parties with
respect to the subject matter hereof including without limitation the Technology
License Agreement between the Parties dated as of July 30, 1999.
11.12 Injunctive Relief. OSI acknowledges that, in the event of its
breach or threatened breach of any of the provisions of this Agreement, CADUS
would sustain great and irreparable injury and damage. Therefore, in addition to
any other remedies which CADUS may have under this Agreement or otherwise, CADUS
shall be entitled to an injunction issued by any court of competent jurisdiction
restraining such breach or threatened breach. This Section 11.12 shall not,
however, be construed as a waiver of any of the rights which CADUS may have for
damages or otherwise.
11.13 Counterparts. This Agreement may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature of
more than one Party but all such counterparts taken together shall constitute
one and the same agreement.
11.14 Descriptive Headings. The descriptive headings of this Agreement
are for convenience only and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.
18
<PAGE>
IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed by its duly authorized officer as of the date first above written.
CADUS PHARMACEUTICAL CORPORATION
By: /s/ Charles Woler
-----------------------------
Charles Woler, President
OSI PHARMACEUTICALS, INC.
By: /s/ Colin Goddard
----------------------------
Colin Goddard, President
and Chief Executive Officer
19
<PAGE>
EXHIBIT A
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------------------------------------------------------
STRAIN_ID MATINGTYPE GENOTYPENEW P1NAME P2NAME P3NAME
- ----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
1141 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
1316 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
1455 a FUS1p-HIS3 bar1::hisG far1-1 his3 leu2
ste14::TRP1 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
1892 a FUS1p-HIS3 bar1::hisG his3 leu2 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
4600 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156
ste4*2393 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
6259 a FUS1p-HIS3 bar1::hisG far1-1 his3 leu2 lys2
ste14::trp1::LYS2 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
6492 a FUS1p-HIS3 bar1::hisG far1*1442 his3 leu2 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
6550 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 npr2::nFUS1p-CAN1 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
7967 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i3 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
8342 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K
his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
8344 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K;
D229S his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
8350 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sD229S
his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
8362 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sE10K CP1584 CP1766
his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
8719 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1(41)-G@i2 his3 leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9034 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-
G@16(S270P) his3 leu2 lys2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9434 @ FUS1p-HIS3 can1 cyh2 far1*1442 gpa1(41)-G@i2
his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9438 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9571 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9595 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3 CP1584 CP3776
lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9603 @ D314) FUS1p-HIS3 L291, can1 far1*1442
gpa1(41)-G@16(S270P, his3 leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9664 a FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9791 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1*1163 his3 leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
9805 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 CP3390 CP4110
leu2 lys2 ste14::trp1::LYS2 ste18g6-
3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9863 @ FUS1p-HIS3 ade2*3447ade8*3457 can1
far1*1442 gpa1(41)-G@16(S270P) his3 leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9875 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1p-rG@sE10K his3 leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
9881 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 CP1947 CP3390 CP4110
leu2 lys2 ste14::trp1::LYS2 ste18g6-
3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10091 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1*1163 his3 leu2 lys2
ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10097 trp1-289
- ----------------------------------------------------------------------------------------------------------------------------------
10098 gal4
- ----------------------------------------------------------------------------------------------------------------------------------
10099 ade
- ----------------------------------------------------------------------------------------------------------------------------------
10100 leu
- ----------------------------------------------------------------------------------------------------------------------------------
10101 lys
- ----------------------------------------------------------------------------------------------------------------------------------
10103 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1 cyh2
far1*1442 gpa1(41)-G@i2 his3 leu2
lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
10106 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1
far1*1442 gpa1p-rG@sE10K;D229S his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10131 @ FUS1p-HIS3 GPA1-3907 ade2*3447 ade8*3457 can1
far1*1442 his3 leu2 lys2 ste14::trp1::LYS2
ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10132 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1(41)-G@16(S270P) his3 leu2
lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10151 @ FUS1p-HIS3 GPA1p-G@sD229S ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10175 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1p-rG@sD229S his3 leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10199 ura
- ----------------------------------------------------------------------------------------------------------------------------------
10319 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 far1*1442 gpa1(41)-G@i3 his3 leu2 lys2
ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10519 @ FUS1p-HIS3 GPA1p-G@sE10K ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10560 @ FUS1p-HIS3 GPA1-3907 ade2*3447 ade8*3457
can1 far1*1442 his3 leu2 lys2 sst2*1056
ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10562 @ FUS1p-HIS3 S270P can1 far1*1442 gpa1(41)-
G@16 his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-
3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10565 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442
his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
10652 @ FUS1p-HIS3 GPA1p-ratG@i1 ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
ste14::trp1::LYS2 ste18g6-3841 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10734 a FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste2*
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10771 a ade1 cdc24-1 his2 leu2 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10772 a ade1 cdc42-1 his2 leu2 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10942 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste18g601-
4060 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
10981 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11063 @ FUS1p-HIS3 GPA1p-G@sE10K can1 far1*1442
his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11066 @ FUS1p-HIS3 GPA1p-G@sE10K;D229S
ade2*3447 ade8*3457 can1 far1*1442 his3 leu2
lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11067 @ FUS1p-HIS3 GPA1p-G@sE10K;D229S can1
far1*1442 his3 leu2 lys2 ste14::trp1::LYS2
ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11366 a FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 ste14::trp1::LYS2 ste2* ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11368 a FUS1p-HIS3 can1 far1*1442 gpa1p-G@sD229S
his3 leu2 lys2 ste14::trp1::LYS2 ste2* ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
11647 a FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3
leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11714 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sG226A
his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11715 @ FUS1p-HIS3 can1 far1*1442 gpa1p-rG@sQ227L
his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11777 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 CP1947 CP3390 CP4421
leu2 lys2 ste14::trp1::LYS2 ste18g601-
4060 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11778 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 CP1179 CP1947 CP4261
leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
11845 @ FUS1p-HIS3 ade2*3447 ade8*3457 can1
far1*1442 gpa1*1163 his3 leu2 lys2
sst2*1056 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12025 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442
leu2 lys2 ste14::trp1::LYS2 ste3*1156
stp22::TRP1ste18g6-3841 tbt1-1
trp1his3ade2*3447ade8*3457 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12201 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste18g6-
3841 ste3*1156 stp22::hisG tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12220 a FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i2 his3
leu2 lys2 ste14::trp1::LYS2 ste2*1154 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12357 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156
stp22::hisG tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12444 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 ste14::trp1::LYS2 ste3*1156 ste5 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
12660 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@i3 his3 CP1584 CP5095
leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12670 @ FUS1p-HIS3 GPA1p-G@sN254D can1 far1*1442
his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12872 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-
G@i2A235T his3 leu2 lys2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12946 @ FUS1p-HIS3 GPA1G@i2(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12949 @ FUS1p-HIS3 GPA1-G@12(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12950 @ FUS1p-HIS3 GPA1-G@q(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12952 @ FUS1p-HIS3 GPA1-G@s(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12954 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2
ste18*2377 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12970 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste20::KanR
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
12971 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 ste14::trp1::LYS2 ste20::KanR
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13189 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 CP1947 CP3390 CP5116
leu2 lys2 ste14::trp1::LYS2 ste18g6-
3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
13193 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2
ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13385 @ FUS1p-HIS3 GPA1G@i2(5) ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
sst2*1056 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13387 @ FUS1p-HIS3 GPA1G@12(5) ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
sst2*1056 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13389 @ FUS1p-HIS3 GPA1G@q(5) ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
sst2*1056 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13391 @ FUS1p-HIS3 GPA1G@s(5) ade2*3447
ade8*3457 can1 far1*1442 his3 leu2 lys2
sst2*1056 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13393 @ FUS1p-HIS3 GPA1G@i2(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13395 @ FUS1p-HIS3 GPA1G@12(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13397 @ FUS1p-HIS3 GPA1G@q(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13399 @ FUS1p-HIS3 GPA1G@s(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13771 @ FUS1p-HIS3 can1 far1*1442 gpa1(41)-G@16
his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13934 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 CP1947 CP4259 CP5298
leu2 lys2 ste14::trp1::LYS2 ste18g6-
3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
13937 @ FUS1p-HIS3 can1 cyh2 far1*1442 gpa1(41)-G@i2
his3 leu2 lys2 ste14::trp1::LYS2 ste18g26-5261
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
13947 @ FUS1p-HIS3 STE18g26-5363 can1 far1*1442
gpa1*1163 his3 leu2 lys2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14011 @ FUS1p-HIS3 GPA1p-G@sE10K can1 far1*1442 CP1584 CP5396
his3 leu2 lys2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14012 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442 CP1947 CP5394
leu2 lys2 ste14::trp1::LYS2 ste3*1156
stp22::TRP1ste18g6-3841 tbt1-1
trp1his3ade2*3447ade8*3457 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14016 @ FUS1p-HIS3 can1 far1*1442 gpa1::klURA3 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g6-3841
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14078 @ FUS1p-HIS3 ade2*3447 ade8*3457
can1 cyh2 far1*1442 gpa1(41)-G@i2 his3 leu2
lys2 ste14::trp1::LYS2 ste18g6-3841 ste3*1156
ste5*4276 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14637 @ E10K FUS1p-HIS3 GPA1p-G@s can1 far1*1442
his3 leu2 lys2 pho3*4602 pho4::KAN
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14638 @ E10K;A249T FUS1p-HIS3 GPA1p-G@s can1
cyh2 far1*1442 his3 leu2 lys2 ste14::trp1::LYS2
ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14640 @ FUS1p-HIS3 GPA1p-GPA1-G@z(5) can1 cyh2
far1*1442 his3 leu2 lys2 ste14::trp1::LYS2
ste18g6-3841 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
14706 @ ste18g6-3841 GPA+3907 sst2*2 far1*1442 tbt1-1
fus1-HIS3 can1 ste14::trp1::LYS2 ste3*1156 lys2
ura3 leu2 trp1 his3
- ----------------------------------------------------------------------------------------------------------------------------------
15070 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
15072 @ FUS1p-HIS3 GPA1G@16(6) STE18g6-3841 can1
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15074 @ FUS1p-HIS3 GPA1G@13(5) STE18g6-3841 can1
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15203 a lys9
- ----------------------------------------------------------------------------------------------------------------------------------
15204 @ lys9
- ----------------------------------------------------------------------------------------------------------------------------------
15347 @ FUS1p-HIS3 GPA1G@z(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15349 @ FUS1p-HIS3 GPA1G@13(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15351 @ FUS1p-HIS3 GPA1G@16(6) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15427 @ E10K FUS1p-HIS3 GPA1p-G@s can1 far1*1442 CP1766 CP5223
his3 leu2 lys2 pho3*4602 pho4::KAN
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15659 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 sst2*2 ste14::trp1::LYS2 ste3*1156
stp22::hisG tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
15836 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2 CP1930 CP1947 CP5042
lys2 sst2*2 ste14::trp1::LYS2 ste3*1156
stp22::hisG tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
16160 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste18g26-5363
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
16463 @ FUS1p-HIS3 GPA1p-G@sD229S can1 far1*1442
his3 leu2 lys2 ste14::trp1::LYS2 ste18g26-5363
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
16637 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1::TRP1::nFUS1p-GFPS65T
ura3::URA3::nFUS1p-GFPS65T
- ----------------------------------------------------------------------------------------------------------------------------------
16961 @ FUS1p-HIS3 GPA1p-G@sD229S STE18g6-3841
ade2*3447 ade8*3457 can1 far1*1442 his3 leu2
lys2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17002 @ FUS1p-HIS3 G@q(1-11)-GPA1(6-467)-G@q(5)
STE18g6-3841 can1 far1*1442 his3 leu2 lys2
sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17004 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 his3
leu2 lys2 ratG@sE10K-G@q(6) sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17007 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442 his3
leu2 lys2 ratG@sD229S-G@q(6) sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17008 @ FUS1p-HIS3 GPA1-G@s(6) STE18g6-3841 can1
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17010 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5)
STE18g6-3841 can1 far1*1442 his3 leu2 lys2
sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17012 @ FUS1p-HIS3 G@q(1-11)-GPA1(6-467)-G@q(5)
can1 far1*1442 his3 leu2 lys2 sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17014 @ FUS1p-HIS3 can1 far1*1442 his3 leu2 lys2
ratG@sE10K-G@q(6) sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17016 @ FUS1p-HIS3 can1 far1*1442 his3 leu2 lys2
ratG@sD229S-G@q(6) sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
17018 @ FUS1p-HIS3 GPA1-G@s(6) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17020 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5)
can1 far1*1442 his3 leu2 lys2 sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17062 @ FUS1p-HIS3 GPA1-G@i2(5) can1 far1*1442 his3
leu2 lys2 pho3*4602 pho4::KAN sst2*1056
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17063 @ FUS1p-HIS3 GPA1-G@q(5) can1 far1*1442 his3
leu2 lys2 pho3*4602 pho4::KAN sst2*1056
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17426 @ FUS1p-HIS3 his3 lys2 sst2*2 GPA1G@q(5) can1
far1*1442 leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1
trp1 ura3 STE18g26-5363
- ----------------------------------------------------------------------------------------------------------------------------------
17549 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
kre1::HisG leu2 lys2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17551 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3
kre1::HisG leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17553 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442
gpa1*1163 his3 kre1::HisG leu2 lys2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17555 @ FUS1p-HIS3 STE18g6-3841 can1 far1*1442
gpa1*1163 his3 kre1::HisG leu2 lys2 sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17624 a FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17625 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
17626 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-17 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17627 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-39 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17628 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-43 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17629 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-61 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17630 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-63 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17631 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-64 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17632 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-16 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17633 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-17 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17634 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-39 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17635 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-43 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17636 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-61 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
17637 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-63 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17638 @ FUS1p-HIS3 can1 far1*1442 gpa1*1163 his3 leu2
lys2 nap-64 sst2*2 ste14::trp1::LYS2 ste3*1156
tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17749 @ FUS1p-HIS3 GPA1G@s(5) STE18g6-3841 can1 CP1584 CP1947 CP6281
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17750 @ FUS1p-HIS3 GPA1G@s(5) STE18g6-3841 can1 CP1584 CP1947 CP6281
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17751 @ FUS1p-HIS3 GPA1-G@i2(5) can1 dap2*6253
far1*1442 his3 leu2 lys2 sst2*2 ste13*6077
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17843 a FUS1p-HIS3 bar1::hisG far1*1442 gpa1*1163
his3 leu2 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17879 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2::LEU2::PGKp-A2aR lys2 sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
17880 a FUS1p-HIS3 bar1::hisG his3 leu2 sst2*1056
ste2*1154 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18039 @ FUS1p-HIS3 GPA1p-G@sD229S STE18g6-3841 CP1584 CP1947 CP4111
ade2*3447 ade8*3457 can1 far1*1442 his3 leu2
lys2 ste14::trp1::LYS2 ste3*1156 stp22::hisG tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18043 @ FUS1p-HIS3 GPA1G@o(5) STE18g6-3841 can1
far1*1442 his3 leu2 lys2 sst2*2 ste14::trp1::LYS2
ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18045 @ FUS1p-HIS3 GPA1G@o(5) can1 far1*1442 his3
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
18158 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2
ste3*1156 stp22::hisG tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18189 @ FUS1p-HIS3 GPA1-3907 can1 far1*1442 his3
leu2 lys2 nap-16 sst2*2 ste14::trp1::LYS2
ste3*1156 stp22::hisG tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18190 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1
far1*1442 his3 kre1::hisG leu2 lys2 sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18222 @ FUS1p-HIS3 GPA1G@z(5) STE18g6-3841 can1 CP1947 CP6131
far1*1442 his3 kre1::hisG leu2 lys2 sst2*2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
18774 @ FUS1p-HIS3 lys2 can1 far1*1442 his3 leu2
pho3*4602 pho4::KAN sst2*1056
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
GPA1p-GPA1-G@s(6)
- ----------------------------------------------------------------------------------------------------------------------------------
19029 @ FUS1p-HIS3 G@q(1-21)-GPA1(24-467)-G@q(5)
STE18g6-3841 can1 far1*1442 his3 kre1::HisG
leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-
1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
19039 @ FUS1p-HIS3 GPA1p-GPA1-G@s(6) can1 CP5226 CP6281
far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN
sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
19055 @ FUS1p-HIS3 GPA1p-GPA1-G@s(6) can1 CP5226 CP1766
far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN
sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
19063 @ FUS1p-HIS3 GPA1-G@q(5) GPA1G@q(5) can1 CP6513 CP1930
far1*1442 his3 leu2 lys2 pho3*4602 pho4::KAN
sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1
ura3
- ----------------------------------------------------------------------------------------------------------------------------------
19493 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
GPA1p-G@11(1-11)-GPA1(6-467)-G@q(355-
359)-GPA1t
- ----------------------------------------------------------------------------------------------------------------------------------
19496 @ FUS1p-HIS3 his3 lys2 GPA1G@q(5) can1 cyh2
far1*1442 leu2 pho3*4602 pho4::KANMX2
sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1
ura3 trp1::TRP1::STE12p-
SV40NLS(MGAPPKKKRKVA)-PHO4(228-312)-
STE12(1-587,EAS,670-688)-ADH1t
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
19507 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
GPA1p-G@q(1-24)-GPA1(27-467)-G@q(355-
359)-GPA1t
- ----------------------------------------------------------------------------------------------------------------------------------
19509 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
GPA1p-G@q(1-32)-GPA1(35-467)-G@q(355-
359)-GPA1t
- ----------------------------------------------------------------------------------------------------------------------------------
19511 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g6-3841 GPA1p-G@11(1-11)-GPA1(6-
467)-G@q(355-359)-GPA1t
- ----------------------------------------------------------------------------------------------------------------------------------
19512 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g6-3841 GPA1p-G@11(1-11)-GPA1(6-
467)-G@q(355-359)-GPA1t
- ----------------------------------------------------------------------------------------------------------------------------------
19513 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g6-3841
- ----------------------------------------------------------------------------------------------------------------------------------
19514 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g6-3841
- ----------------------------------------------------------------------------------------------------------------------------------
19515 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g6-3841 GPA1p-G@q(1-32)-GPA1(35-
467)-G@q(355-359)-GPA1t
- ----------------------------------------------------------------------------------------------------------------------------------
19598 @ FUS1p-HIS3 GPA1-G@i2(5) his3 lys2 can1 CP6555 CP5095
far1*1442 leu2 pho3*4602 pho4::KAN sst2*1056
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
- ----------------------------------------------------------------------------------------------------------------------------------
19608 @ FUS1p-HIS3 lys2 can1 far1*1442 gpa1*1163 his3
leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g26-5363 GPA1-G@s(5)-5102
- ----------------------------------------------------------------------------------------------------------------------------------
19608 @ FUS1p-HIS3 lys2 can1 far1*1442 gpa1*1163 his3
leu2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
STE18g26-5363 GPA1-G@s(5)-5102
- ----------------------------------------------------------------------------------------------------------------------------------
19625 @ FUS1p-HIS3 his3 lys2 GPA1G@q(5) can1 cyh2 CP1930
far1*1442 leu2 pho3*4602 pho4::KANMX2
sst2*1056 ste14::trp1::LYS2 ste3*1156 tbt1-1
ura3 trp1::TRP1::STE12p-
SV40NLS(MGAPPKKKRKVA)-PHO4(228-312)-
STE12(1-587,EAS,670-688)-ADH1t
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------------------
19888 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2
ade2*3447 ade8*3457 can1 far1*1442 leu2
ste14::trp1::LYS2 ste18*2377 ste3*1156
stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363
- ----------------------------------------------------------------------------------------------------------------------------------
19888 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2
ade2*3447 ade8*3457 can1 far1*1442 leu2
ste14::trp1::LYS2 ste18*2377 ste3*1156
stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363
- ----------------------------------------------------------------------------------------------------------------------------------
19889 @ FUS1p-HIS3 GPA1p-G@sD229S his3 lys2 CP6280 CP5899 CP6684
ade2*3447 ade8*3457 can1 far1*1442 leu2
ste14::trp1::LYS2 ste18*2377 ste3*1156
stp22::hisG tbt1-1 trp1 ura3 ste18g26-5363
- ----------------------------------------------------------------------------------------------------------------------------------
19910 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
GPA1G@z(5) STE18g6-3841
- ----------------------------------------------------------------------------------------------------------------------------------
19928 @ FUS1p-HIS3 his3 lys2 sst2*2 can1 far1*1442 leu2 CP6490 CP1584
ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3
GPA1G@16(6)
- ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
All Mammalian Cell Lines
<PAGE>
EXHIBIT B
Note: US Provisional Applications have serial numbers starting with "60" and
docket number ending in "-1"
Note: Foreign Applications are shown in Bold w/ Shading
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C>
Docket No. Serial No. Title: Filing Date Status
CPI-012CP9 09/201,396 Methods and Compositions for 11/30/98 PENDING
Identifying Receptor Effectors
CPI-012CP9PC PCT/US99/27909 Methods and Compositions for 11/24/99 PENDING
Identifying Receptor Effectors
CPI-088 09/378,046 Cells Having Amplified Signal 8/30/99 PENDING
Transduction Pathway Responses
and Uses Therefor
CPI-091 09/305,923 Yeast Cells Having Mutations 5/5/99 PENDING
in STP22 and Uses Therefor
CPI-096 09/426,332 Yeast Cells Having Mutations 10/25/99 PENDING
in CAV1 and Uses Therefor
CPI-099 09/362,286 Expression of G Protein 7/27/99 PENDING
Coupled Receptors with Altered
Ligand Binding and/or Coupling
Properties
CPI-102 09/241,888 Cell Based Signal Generation 2/1/99 PENDING
CPI-122-1 60/153,300 Yeast Alpha Agglutinins and 9/10/99 PENDING
Use Thereof as Indicators of (Conversion
Activation of the Yeast date is 9/09/00)
Pheromone Response Pathway
CPI-123-1 60/139,021 Mating Factor System for 6/14/99 PENDING
Detection of a Functional Inter- (Conversion
action Between A Compound date is 6/13/00)
and a Cellular Receptor
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Balance Sheet, and Income Statement and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-END> MAR-31-2000
<CASH> 5,855,655
<SECURITIES> 0
<RECEIVABLES> 110,140
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 6,102,755
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 27,205,543
<CURRENT-LIABILITIES> 615,424
<BONDS> 0
132,857
0
<COMMON> 0
<OTHER-SE> 7,147,042
<TOTAL-LIABILITY-AND-EQUITY> 27,205,543
<SALES> 0
<TOTAL-REVENUES> 700,000
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 852,462
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (341,119)
<INCOME-TAX> 0
<INCOME-CONTINUING> (341,119)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> (341,119)
<NET-INCOME> 0
<EPS-BASIC> (0.03)
<EPS-DILUTED> (0.03)
</TABLE>
